Winning Health Technology Group Yönetim

Yönetim kriter kontrolleri 2/4

Winning Health Technology Group CEO'su Tao Wang, Nov2014 tarihinde atandı, in görev süresi 6.67 yıldır. şirketin hisselerinin 0.048% doğrudan sahiptir ve bu hisselerin değeri CN¥ 8.01M dir. Yönetim ekibinin ve yönetim kurulunun ortalama görev süresi sırasıyla 10.6 yıl ve 7.1 yıldır.

Anahtar bilgiler

Tao Wang

İcra Kurulu Başkanı

CN¥1.8m

Toplam tazminat

CEO maaş yüzdesi	n/a
CEO görev süresi	10yrs
CEO sahipliği	0.05%
Yönetim ortalama görev süresi	10.6yrs
Yönetim Kurulu ortalama görev süresi	7.1yrs

Son yönetim güncellemeleri

Recent updates

There May Be Underlying Issues With The Quality Of Winning Health Technology Group's (SZSE:300253) Earnings

Nov 05

Winning Health Technology Group Co., Ltd. (SZSE:300253) Held Back By Insufficient Growth Even After Shares Climb 39%

Oct 10

Winning Health Technology Group (SZSE:300253) May Have Issues Allocating Its Capital

Aug 22

These 4 Measures Indicate That Winning Health Technology Group (SZSE:300253) Is Using Debt Reasonably Well

Jul 03

Impressive Earnings May Not Tell The Whole Story For Winning Health Technology Group (SZSE:300253)

May 03

Is Winning Health Technology Group (SZSE:300253) A Risky Investment?

Mar 19

Winning Health Technology Group Co., Ltd. (SZSE:300253) Held Back By Insufficient Growth Even After Shares Climb 25%

Mar 01

Returns On Capital At Winning Health Technology Group (SZSE:300253) Paint A Concerning Picture

Feb 28

CEO

Tao Wang (55 yo)

10yrs

Görev süresi

CN¥1,799,900

Tazminat

Mr. Tao Wang serves as General Manager of Winning Health Technology Group Co., Ltd., since November 17, 2014 and its Director since March 16, 2018. Mr. Wang was Software Engineer for Shanghai Computer Soft...

Liderlik Ekibi

İsim	Pozisyon	Görev süresi	Tazminat	Sahiplik
Tao Wang	GM & Director	10yrs	CN¥1.80m	0.048% CN¥ 8.0m
Li Wang	Chief Financial Officer	11.2yrs	CN¥541.90k	0.055% CN¥ 9.1m
Jia Ming Sun	Senior Vice President	10yrs	CN¥981.90k	0.11% CN¥ 18.6m
Mao Jin	Senior VP	15.9yrs	CN¥681.90k	0.33% CN¥ 54.6m

10.6yrs

Ortalama Görev Süresi

49yo

Ortalama Yaş

Deneyimli Yönetim: 300253 'un yönetim ekibi deneyimli ve deneyimlidir ( 10.6 yıldır).

Yönetim Kurulu Üyeleri

İsim	Pozisyon	Görev süresi	Tazminat	Sahiplik
Tao Wang	GM & Director	6.7yrs	CN¥1.80m	0.048% CN¥ 8.0m
Mao Jin	Senior VP	15.4yrs	CN¥681.90k	0.33% CN¥ 54.6m
Wei Zhou	Chairman	15.9yrs	CN¥1.10m	8.22% CN¥ 1.4b
Ning Liu	Vice Chairman	15.9yrs	CN¥1.10m	4.83% CN¥ 797.8m
Lin Li	Chairman of the Supervisory Board	11.3yrs	CN¥117.70k	Veri yok
Weihong He	Supervisor	7.5yrs	Veri yok	Veri yok
Baojing Yao	Independent Director	6.7yrs	CN¥80.00k	Veri yok
Jinfeng Feng	Independent Director	3.8yrs	CN¥80.00k	Veri yok
Weisong Wang	Independent Director	3.8yrs	CN¥80.00k	Veri yok
Yanna Lu	Supervisor	3.8yrs	Veri yok	Veri yok

7.1yrs

Ortalama Görev Süresi

49yo

Ortalama Yaş

Deneyimli Yönetim Kurulu: 300253 'nin yönetim kurulu üyeleri deneyimli olarak kabul edilir (ortalama görev süresi 7.1 yıldır).

Winning Health Technology Group Yönetim

Yönetim kriter kontrolleri 2/4

Anahtar bilgiler

Son yönetim güncellemeleri

Winning Health Technology Group Co., Ltd., Annual General Meeting, May 10, 2024

Less than half of directors are independent

Less than half of directors are independent

Winning Health Technology Group Co., Ltd. Announces Board Appointments

Recent updates

There May Be Underlying Issues With The Quality Of Winning Health Technology Group's (SZSE:300253) Earnings

Price target increased by 13% to CN¥8.83

Third quarter 2024 earnings released: EPS: CN¥0.057 (vs CN¥0.064 in 3Q 2023)

Investor sentiment deteriorates as stock falls 17%

Winning Health Technology Group Co., Ltd. (SZSE:300253) Held Back By Insufficient Growth Even After Shares Climb 39%

New minor risk - Share price stability

Winning Health Technology Group Co., Ltd. to Report Q3, 2024 Results on Oct 30, 2024

Investor sentiment improves as stock rises 17%

Price target decreased by 9.5% to CN¥8.14

Second quarter 2024 earnings released: EPS: CN¥0.006 (vs CN¥0.037 in 2Q 2023)

Winning Health Technology Group (SZSE:300253) May Have Issues Allocating Its Capital

These 4 Measures Indicate That Winning Health Technology Group (SZSE:300253) Is Using Debt Reasonably Well

Winning Health Technology Group Co., Ltd. to Report First Half, 2024 Results on Aug 29, 2024

Dividend increased to CN¥0.02

Impressive Earnings May Not Tell The Whole Story For Winning Health Technology Group (SZSE:300253)

First quarter 2024 earnings released: EPS: CN¥0.008 (vs CN¥0.03 loss in 1Q 2023)

Full year 2023 earnings: EPS and revenues miss analyst expectations

Winning Health Technology Group Co., Ltd., Annual General Meeting, May 10, 2024

Price target increased by 12% to CN¥9.08

Winning Health Technology Group Co., Ltd. to Report Q1, 2024 Results on Apr 27, 2024

Is Winning Health Technology Group (SZSE:300253) A Risky Investment?

Winning Health Technology Group Co., Ltd. (SZSE:300253) Held Back By Insufficient Growth Even After Shares Climb 25%

Returns On Capital At Winning Health Technology Group (SZSE:300253) Paint A Concerning Picture

Winning Health Technology Group Co., Ltd. to Report Fiscal Year 2023 Results on Apr 13, 2024

Price target decreased by 7.5% to CN¥9.29

Third quarter 2023 earnings: Revenues and EPS in line with analyst expectations

Consensus revenue estimates fall by 10%

Second quarter 2023 earnings: Revenues and EPS in line with analyst expectations

Winning Health Technology Group Co., Ltd. to Report First Half, 2023 Results on Aug 18, 2023

Winning Health Technology Group Co., Ltd. Announces Final Dividend Implementation on Share A for 2022, Payable on June 15, 2023

Price target increased by 8.5% to CN¥12.35

Full year 2022 earnings: EPS and revenues miss analyst expectations

Price target increased to CN¥10.04

Less than half of directors are independent

Consensus EPS estimates fall by 62%

Third quarter 2022 earnings: EPS in line with expectations, revenues disappoint

Investor sentiment improved over the past week

Second quarter 2022 earnings released: EPS: CN¥0.016 (vs CN¥0.046 in 2Q 2021)

Winning Health Technology Group Co., Ltd. Announces Final Dividend on A Shares for the Year 2021, Payable on July 15, 2022

Winning Health Technology Group Co., Ltd. Announces Final Dividend for 2021

Consensus EPS estimates fall by 23%

Price target decreased to CN¥11.04

First quarter 2022 earnings: EPS misses analyst expectations

Less than half of directors are independent

Winning Health Technology Group Co., Ltd. Proposes Final Dividend for 2021

Now 20% undervalued after recent price drop

Now 21% undervalued after recent price drop

Consensus EPS estimates fall by 10%

Price target decreased to CN¥15.54

Investor sentiment deteriorated over the past week

Price target decreased to CN¥15.79

Price target decreased to CN¥17.39

Third quarter 2021 earnings released: EPS CN¥0.07 (vs CN¥0.061 in 3Q 2020)

Second quarter 2021 earnings released: EPS CN¥0.046 (vs CN¥0.029 in 2Q 2020)

Full year 2020 earnings released: EPS CN¥0.23 (vs CN¥0.19 in FY 2019)

Winning Health Technology Group Co., Ltd. to Report Fiscal Year 2020 Results on Apr 21, 2021

Price target lowered to CN¥20.45

Winning Health Technology Group Co., Ltd. Announces Board Appointments

New 90-day high: CN¥17.90

New 90-day low: CN¥14.86

New 90-day low: CN¥14.95

New 90-day low: CN¥15.54

New 90-day low: CN¥16.63

New 90-day low: CN¥17.79

Third quarter earnings released

Suqian Jingdong Tianning Health Technology Co., Ltd. and Wuxi AppTec Phase I Investment Enterprise (Limited Partnership) completed the acquisition of 8.6% stake in Shanghai Kingstar Winning Software Technology Co., Ltd. from Zhao Menghai and Winning Health Technology Group Co., Ltd. (SZSE:300253).

Earnings released

Winning Health Technology Group Co., Ltd. to Report First Half, 2020 Results on Aug 27, 2020

CEO

Görev süresi

Tazminat